John J O'Connor

US Patent:

6927034, Aug 9, 2005

Filed:

May 13, 1999

Appl. No.:

09/311428

Inventors:

John O'Connor - New Rochelle NY, US
Steven Birken - Dumont NJ, US
Galina Kovalevskaya - Bronx NY, US

Assignee:

The Trustees of Columbia University in the City of New York - New York NY

International Classification:

G01N033/543
G01N033/537

US Classification:

435 792, 435 71, 435 75, 435 79, 435 794, 436501, 436814, 436818, 5303875, 53038824, 5303892

Abstract:

The present invention provides a method of predicting pregnancy outcome in a subject by determining the amount of an early pregnancy associated molecular isoform of hCG in a sample. The present invention further provides a method for determining the amount of early pregnancy associated molecular isoforms of human chorionic gonadotropin (hCG) in a sample. The present invention also provides a diagnostic kit for determining the amount of early pregnancy associated hCG in a sample. The present invention additionally provides an antibody which specifically binds to an early pregnancy associated molecular isoform of human chorionic gonadotropin. Finally, the present invention provides methods for detecting trophoblast or non-trophoblast malignancy in a sample.

US Patent:

7034124, Apr 25, 2006

Filed:

Sep 23, 1999

Appl. No.:

09/404076

Inventors:

Robert E. Canfield - Cold Spring NY, US
Steven Birken - Dumont NJ, US
John O'Connor - New Rochelle NY, US
Galina Kovalevskaya - New York NY, US

Assignee:

The Trustees of Columbia University in the City of New York - New York NY

International Classification:

C07K 16/00

US Classification:

5303892, 53038824

Abstract:

This invention provides an antibody which specifically binds to hLHβcf without cross-reacting with hLH, hLHβ or hCGβcf. In an embodiment, the monoclonal antibody is designated B505. In a further embodiment, the hybridoma cell line producing the monoclonal antibody B 505 is designated ATCC Accession No. 12000. This invention provides different uses of the antibodies. Finally, this invention provides a method for determining the amount of hLHβcf or hLHβcf-related molecule in a sample.

US Patent:

7198954, Apr 3, 2007

Filed:

Aug 1, 2000

Appl. No.:

09/630215

Inventors:

John F. O'Connor - New Rochelle NY, US
Galina I. Kovalevskaya - New York NY, US
Steven Birken - Dumont NJ, US

Assignee:

The Trustees of Columbia University in the City of New York - New York NY

International Classification:

G01N 33/48
G01N 33/53
C07K 16/00

US Classification:

436 65, 435 71, 435 75, 435 792, 435 794, 436501, 436518, 436524, 436528, 436811, 436547, 436548, 5303875, 53038824, 5303892

Abstract:

The present invention provides a method of predicting pregnancy outcome in a subject by determining the amount of an early pregnancy associated molecular isoform of hCG in a sample. The present invention further provides a method for determining the amount of early pregnancy associated molecular isoforms of human chorionic gonadotropin (hCG) in a sample. The present invention also provides a diagnostic kit for determining the amount of early pregnancy associated hCG in a sample. The present invention additionally provides an antibody which specifically binds to an early pregnancy associated molecular isoform of human chorionic gonadotropin. Finally, the present invention provides methods for detecting trophoblast or non-trophoblast malignancy in a sample.

US Patent:

7229781, Jun 12, 2007

Filed:

May 31, 2002

Appl. No.:

10/159354

Inventors:

Steven Birken - Dumont NJ, US
Yacov Maydelman - Fort Lee NJ, US
Galina I. Kovalevskaya - New York NY, US
John F. O'Connor - New Rochelle NY, US

Assignee:

The Trustees of Columbia University in the City of New York - New York NY

International Classification:

G01N 33/50
G01N 33/53
G01N 33/536
G01N 33/537
G01N 33/541

US Classification:

435 792, 435 71, 435 75, 5303871

Abstract:

The present invention provides methods to quantitate the hLHβ core fragment in a sample. The present invention now makes it possible to evaluate the metabolism of hLH in premenopausal, perimenopausal and postmenopausal women and to distinguish between normal and abnormal physiological states.

US Patent:

7285391, Oct 23, 2007

Filed:

Sep 1, 2004

Appl. No.:

10/931956

Inventors:

John O'Connor - New Rochelle NY, US
Steven Birken - Dumont NJ, US
Galina Kovalevskaya - Bronx NY, US

Assignee:

The Trustees of Columbia Univeristy in the City of New York - New York NY

International Classification:

G01N 33/00
G01N 33/53
A61K 39/395

US Classification:

435 71, 435 75, 435 79, 435 792, 435 794, 436501, 436814, 436818, 5303875, 53038824, 5303892, 4241301

Abstract:

The present invention provides a method of predicting pregnancy outcome in a subject by determining the amount of an early pregnancy associated molecular isoform of hCG in a sample. The present invention further provides a method for determining the amount of early pregnancy associated molecular isoforms of human chorionic gonadotropin (hCG) in a sample. The present invention also provides a diagnostic kit for determining the amount of early pregnancy associated hCG in a sample. The present invention additionally provides an antibody which specifically binds to an early pregnancy associated molecular isoform of human chorionic gonadotropin. Finally, the present invention provides methods for detecting trophoblast or non-trophoblast malignancy in a sample.

US Patent:

7399636, Jul 15, 2008

Filed:

Dec 31, 2002

Appl. No.:

10/335115

Inventors:

John F. O'Connor - New Rochelle NY, US
Galina I. Kovalevskaya - New York NY, US
Steven Birken - Dumont NJ, US

Assignee:

The Trustees of Columbia University in the City of New York - New York NY

International Classification:

G01N 33/48
G01N 33/53
C07K 16/00

US Classification:

436 65, 422 61, 435 71, 435 75, 435 792, 435 794, 436501, 436518, 436524, 436528, 436547, 436548, 5303875, 53038824, 5303892

Abstract:

The present invention provides a method of predicting pregnancy outcome in a subject by determining the amount of an early pregnancy associated molecular isoform of hCG in a sample. The present invention further provides a method for determining the amount of early pregnancy associated molecular isoforms of human chorionic gonadotropin (hCG) in a sample. The present invention also provides a diagnostic kit for determining the amount of early pregnancy associated hCG is a sample. The present invention additionally provides an antibody which specifically binds to an early pregnancy associated molecular isoform of human chorionic gonadotropin. Finally, the present invention provides methods for detecting trophoblast or non-trophoblast malignancy in a sample.

US Patent:

7655410, Feb 2, 2010

Filed:

Feb 10, 2003

Appl. No.:

10/361652

Inventors:

Steven Birken - Dumont NJ, US
Yacov Maydelman - Fort Lee NJ, US
Galina I. Kovalevskaya - New York NY, US
John F. O'Connor - New Rochelle NY, US

Assignee:

The Trustees of Carolina University in the City of New York - New York NY

International Classification:

G01N 33/53
C07K 17/00

US Classification:

435 71, 5303911, 5303913

Abstract:

The present invention provides a method for predicting the likely timing of the onset of menopause for a perimenopausal female subject by determining the amount of hLHβcf in a sample from the subject comprising the steps of: (a) contacting a sample from the subject with an antibody which specifically binds to hLHβcf without substantially cross-reacting with hLH, hLHβ or hLHβcf, under conditions permitting formation of a complex between the antibody and hLHβcf; (b) measuring the amount of complex formed, so as to thereby determine the amount of hLHβcf in the sample; and (c) comprising the amount of hLHβcf in the subject's sample determined in step (b) with either (i) the amount determined for known postmenopausal female subject or (ii) the amount determined for a sample from a known premenopausal female subject, wherein an amount of hLHβcf in the sample similar to the amount of hLHβcf in the known postmenopausal sample indicates temporal proximity to the onset of menopause, and an amount of hLHβcf in the sample similar to the amount of hLHβcf in the known premenopausal sample indicates temporal distance from the onset of menopause for the subject. AS described herein amount is both concentration and pattern of measurement of concentrations in one or more consecutive urine specimens.

US Patent:

7790403, Sep 7, 2010

Filed:

Oct 22, 2007

Appl. No.:

11/975936

Inventors:

John O'Connor - New Rochelle NY, US
Steven Birken - Dumont NJ, US
Galina Kovalevskaya - Bronx NY, US

Assignee:

The Trustees of Columbia University in the City of New York - New York NY

International Classification:

G01N 33/53

US Classification:

435 71, 435 75, 435 79, 435 792, 435 794, 436501, 436814, 436818, 5303875, 53038824, 5303892, 4241301

Abstract:

The present invention provides a method of predicting pregnancy outcome in a subject by determining the amount of an early pregnancy associated molecular isoform of hCG in a sample. The present invention further provides a method for determining the amount of early pregnancy associated molecular isoforms of human chorionic gonadotropin (hCG) in a sample. The present invention also provides a diagnostic kit for determining the amount of early pregnancy associated hCG in a sample. The present invention additionally provides an antibody which specifically binds to an early pregnancy associated molecular isoform of human chorionic gonadotropin. Finally, the present invention provides methods for detecting trophoblast or non-trophoblast malignancy in a sample.